NCT05765500 - RecoverPC: Relugolix vs GnRH Agonist in Quality of Life | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

February 12, 2024

Primary Completion Date

July 1, 2027

Study Completion Date

January 1, 2028

Conditions

Prostate CancerProstatic Neoplasms

Interventions

DRUG

Relugolix

Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.

DRUG

Leuprolide

Gonadotropin-releasing hormone (GnRH) antagonist, intramuscular injection 1x every 3 months.

Trial Locations (3)

NOT_YET_RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

RECRUITING

Dana-Farber Cancer Institute at Foxborough, Foxborough